Topic Archives: MEI Pharma (MEIP)

MEI Pharma ($MEIP) is a NASDAQ-listed $133M biotech based in San Diego that was spun out by prior owner Australian biotech Novogen ($NVGN), a firm now facing NASDAQ delisting for failing to meet requirements, in 2012. Though I can certainly understand the reluctance of rational biotech investors to avoid any firm even vaguely associated with […]

Comments

No comments.

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

More Info